Nicotinamide → (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal

HRID 1486359

반응식

HRID 1486359 반응식
CC(C)=CO[Si](C)(C)C.C[C@H]1C2(C(C)=C3C(C4C(C3)C3(C)C(CC(CC3)=O)=CC4)CC2)O[C@@H]2CC(C)CN(CCNC(CCCCCNC(CCC3C=CC=CC=3)=O)=O)C12.CC1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C(O)=O.C[C@H](NC(CC1C=C(F)C=C(F)C=1)=O)C(N[C@H](C(OC(C)(C)C)=O)C1C=CC=CC=1)=O.CC[C@@H]([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC(CNC([C@@H](N)CC1NC=NC=1)=O)=O)CCC(O)=O)=O)=O)[C@H](O)C)=O)CC1C=CC=CC=1)=O)[C@H](O)C)=O)CO)=O)CC(O)=O)=O)CC(C)C)=O)CO)=O)CCCCN)=O)CCC(N)=O)=O)CCSC)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)C)=O)C(C)C)=O)CCCNC(N)=N)=O)CC(C)C)=O)CC1C=CC=CC=1)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N1[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N2[C@H](C(N3[C@H](C(N4[C@H](C(N[C@H](C(N)=O)CO)=O)CCC4)=O)CCC3)=O)CCC2)=O)C)=O)=O)CO)=O)CO)=O)CCC1)=O)=O)=O)CC(N[C@@H]1O[C@H](CO)[C@@H]([O:175][C@@H:176]2[O:181][C@H:180]([CH2:182][O:183][C@@]3(C(O)=O)O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)[C@H:179]([OH:205])[C@H:178]([OH:206])[C@H:177]2[OH:207])[C@H](O)[C@H]1NC(C)=O)=O)=O)CCCCN)=O)CC(C)C)=O)CC1C2C=CC=CC=2NC=1)=O)CCC(O)=O)=O)C.C(N)(=O)C1C=CC=NC=1>>[O:175]=[CH:176][C@@H:177]([C@H:178]([C@@H:179]([C@@H:180]([CH2:182][OH:183])[OH:181])[OH:205])[OH:206])[OH:207]

참가 물질

7

반응물 6

HCID 936Nicotinamide2회HCID 99685Isobutyraldehyde trimethylsilyl enol ether3회HCID 444795Retinoic AcidHCID 5311272Dapt2회HCID 16760383N-[2-[(3'R,7'aR)-3',6',10,11b-tetramethyl-3-oxospiro[1,2,4,6,6a,6b,7,8,11,11a-decahydrobenzo[a]fluorene-9,2'-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyridine]-4'-yl]ethyl]-6-(3-phenylpropanoylamino)hexanamide2회HCID 49862879CID 498628792회

생성물 1

HCID 107526(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal

실험 절차

Cells were reprogrammed according to Example 11, and were then cultured in DMEM/F12, 100 ng/ml activin A, 25 ng/ml Wnt3a, 0.01% recombinant HSA, 1×ITSE for 1 day, followed by DMEM/F12, 100 ng/ml activin A, 0.01% recombinant HSA, 1×ITSE for 2 days, followed by DMEM/F12, 50 ng/ml FGF10, 0.25 μM KAAD-cyclopamine, 0.01% recombinant HSA, 1×ITSE for 3 days, followed by DMEM/F12, 1% B27, 2 μM all-trans retinoic acid, 50 ng/ml FGF10, 0.25 μM KAAD-cyclopamine for 4 days, followed by DMEM/F12, 1% B27, 1 μM γ-secretase inhibitor DAPT, 50 ng/ml exendin-4, 10 nM betacellulin, 10 mM nicotinamide for 2 days, followed by DMEM/F12, 50 mg/L ascorbic-acid-2-phosphate, 1% B27, 1 μM γ-secretase inhibitor DAPT, 50 ng/ml exendin-4, 50 ng/ml IGF-1, 50 ng/ml HGF, 10 nM betacellulin, 10 mM nicotinamide for 6 days to generate glucose-responsive insulin-producing cells (FIG. 5A). The resulting cells can be used in vitro or in vivo for screening bioactive molecules for the study of diabetes or for the development of therapeutics for diabetes.

후처리

  1. customfor 1 day
  2. customfor 2 days

출처 및 근거

ORD 기록
ord-b37f66fc11ba448e86674f1bc8ce2d4a
출처 데이터셋
uspto-grants-2016_08
특허 번호
US09422577B2

연결된 노트

불러오는 중…